Hormone dependent breast cancers initially respond to endocrine therapy with tumor regression but tumor recurrences are invariable. An understanding of the mechanisms mediating relapse would allow development of strategies to counteract this process. We have provided evidence that tumor cells adapt during treatment by becoming hypersensitive to estradiol, a process which mediates tumor re-growth. We wish to determine precisely what steps induce this adaptive process. Preliminary data suggest a key role for cell cycle events distal to estrogen receptor function. Our hypothesis is that an adaptive process occurs in which growth factor and estradiol mediated events cooperatively interact at a """"""""point of intersection"""""""" in the cell cycle to mediate hypersensitivity. At this """"""""intersection point,"""""""" c-myc, a direct estrogen-mediated early response gene, and products of the growth factor stimulated RAS pathway cooperate to regulate key cell cycle proteins. We postulate that this interaction results in suppression of the cyclin inhibitor p-27, bypass of the need for phosphorylation of the Rb protein, enhanced activation of E2F transcription factors, and an increase in cyclin E kinase activity. To test this hypothesis, we will pursue four specific aims using as a model, breast cancer cells with adaptive hypersensitivity.
Specific Aim 1 will evaluate the role of E2F transcription factors and the cyclins in the process of adaptive hypersensitivity.
Specific Aim 2 will seek to demonstrate down regulation of cyclin inhibitors and resultant effects on E2F levels and cell proliferation. We postulate that adaptation to estrogen deprivation involves down regulation of inhibitors of cyclin dependent kinase activation. We will measure the levels of the two classes of inhibitors, the INK 4 a-d group as well as the Cip-1/Waf-1/Kip1/Kip2 class (p-2l, p-27, p-57). To directly assess cause and effect relationships, we will use stable transfectants to determine if p-27 activation decreases sensitivity to estradiol in LTED deprived cells.
Specific Aim 3 will evaluate the role of growth factor pathways on E2F production. We will use strategies both for induction of hypersensitivity in wild type cells and for reversion of hypersensitive cells back to normal sensitivity. Inhibitors of MAP kinase and RAS plasma membrane binding will be used to interdict the effects of activated RAS in hypersensitive cells and to cause reversion of hypersensitivity. induction of hypersensitivity in wild type cells will involve TGF alpha administration as well as use of tetracycline regulatable, stable transfection constructs to cause over-expression of MAP kinase.
Specific Aim 4 will determine whether LTED deprivation induces antiapoptotic regulatory mechanisms. These studies are expected to identify appropriate targets which could then be used in patients to revert hypersensitive cells back to normal and thereby enhance the duration of hormonal therapy in women with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084456-04
Application #
6626743
Study Section
Special Emphasis Panel (ZRG1-REB (01))
Program Officer
Sathyamoorthy, Neeraja
Project Start
2000-01-01
Project End
2004-08-31
Budget Start
2003-01-01
Budget End
2004-08-31
Support Year
4
Fiscal Year
2003
Total Cost
$299,592
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Santen, Richard J; Song, Robert X; Masamura, Shigeru et al. (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34
Rahman, Mostafizur; Lax, Sigurd F; Sutter, Carrie H et al. (2008) CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. Drug Metab Dispos 36:963-70
Liu, Gui-Jian; Liu, Giujian; Wu, Yu-Sheen et al. (2008) Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. Breast Cancer Res Treat 111:343-51
Yue, Wei; Wang, Jiping; Li, Yuebai et al. (2005) Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 117:746-54
Barnes, C J; Vadlamudi, R K; Kumar, R (2004) Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61:281-91
Mishra, Sandip K; Mazumdar, Abhijit; Vadlamudi, Ratna K et al. (2003) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem 278:19209-19
Mazumdar, Abhijit; Kumar, Rakesh (2003) Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 535:6-10
Kumar, Rakesh; Wang, Rui-An; Bagheri-Yarmand, Rozita (2003) Emerging roles of MTA family members in human cancers. Semin Oncol 30:30-7
Vadlamudi, R K; Wang, R A; Mazumdar, A et al. (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276:38272-9
Mazumdar, A; Wang, R A; Mishra, S K et al. (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-7

Showing the most recent 10 out of 11 publications